Glenmark gets U.S. FDA nod for nasal spray.

Glenmark gets U.S. FDA nod for nasal spray. Glenmark Pharmaceuticals has received U.S. FDA approval for its generic Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray, a widely used corticosteroid for allergic rhinitis. This approval allows Glenmark to launch the product in the U.S., expanding its respiratory portfolio. The U.S. market for this drug was valued at over $200 million annually, offering significant revenue potential.

📊 STOCKS: $GLENMARK | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #FDAApproval